中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

10800 records (took 0.106 seconds)

    Polypeptide homologous to vegf and bmp1
    2.
    发明专利
    Polypeptide homologous to vegf and bmp1 有权
    多肽与VEGF和BMP1的异质性

    公开(公告)号：JP2010001292A

    公开(公告)日：2010-01-07

    申请号：JP2009160434

    申请日：2009-07-07

    Applicant: Genentech Inc ,  ジェネンテック・インコーポレーテッドGenentech,Inc.

    Inventor： FERRARA NAPOLEONE ,  SOPHIA S KUO

    IPC: A61K45/06 ,  G01N33/50 ,  A61K38/00 ,  A61K39/395 ,  A61K45/00 ,  A61P9/00 ,  A61P17/02 ,  A61P19/08 ,  A61P35/00 ,  A61P43/00 ,  C07K14/52 ,  C07K16/24 ,  C07K19/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/18 ,  C12N15/19 ,  C12P21/02 ,  C12P21/08 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/577 ,  G01N33/68

    CPC classification number: C07K14/52 ,  A61K38/00 ,  C07K2319/00 ,  C12N2799/026

    Abstract: PROBLEM TO BE SOLVED: To provide a method for inhibiting or preventing growth of cancer cells. SOLUTION: A VEGF-E (vascular endothelial growth factor-E) antagonist which is a new polypeptide related to VEGF (vascular endothelial growth factor) and bone morphogenetic protein 1 is administered in combination with a second agent. Furthermore, the second agent is a chemotherapeutic agent, a growth inhibitory agent, a cytotoxic agent, an angiostatic agent, an agent used in radiation therapy, an anti-VEGF antibody, an FGF antagonist, a PDGF antagonist, or an antibody that binds to an ErbB2, an EGFR, an ErbB3, an ErbB4 or a VEGF receptor. In addition, the chemotherapeutic agent, the growth inhibitory agent, the cytotoxic agent, the angiostatic agent, the agent used in the radiation therapy, the anti-VEGF antibody, the FGF antagonist, the PDGF antagonist, or the antibody that binds to the ErbB2, the EGFR, the ErbB3, the ErbB4 or the VEGF receptor is administered as a third therapeutic agent. COPYRIGHT: (C)2010,JPO&INPIT

    Abstract translation: 待解决的问题：提供抑制或预防癌细胞生长的方法。 解决方案：与VEGF（血管内皮生长因子）和骨形态发生蛋白1相关的新多肽的VEGF-E（血管内皮生长因子-E）拮抗剂与第二药剂组合施用。 此外，第二药剂是化学治疗剂，生长抑制剂，细胞毒性剂，血管抑制剂，放射治疗剂中使用的药剂，抗VEGF抗体，FGF拮抗剂，PDGF拮抗剂或与 ErbB2，EGFR，ErbB3，ErbB4或VEGF受体。 此外，化学治疗剂，生长抑制剂，细胞毒性剂，血管保护剂，放射治疗剂中使用的药剂，抗VEGF抗体，FGF拮抗剂，PDGF拮抗剂或与ErbB2结合的抗体 ，作为第三治疗剂施用EGFR，ErbB3，ErbB4或VEGF受体。 版权所有（C）2010，JPO＆INPIT

    New use of artemin which is member of gdnf ligand family
    4.
    发明专利
    New use of artemin which is member of gdnf ligand family 审中-公开
    作为GDNF配对家族成员的ARTEMIN的新用途

    公开(公告)号：JP2009263360A

    公开(公告)日：2009-11-12

    申请号：JP2009089196

    申请日：2009-04-01

    Applicant: Genentech Inc ,  ジェネンテック・インコーポレーテッドGenentech,Inc.

    Inventor： SHELTON DAVID L ,  PHILLIPS HEIDI S

    IPC: A61K38/00 ,  A61K45/00 ,  A61K38/18 ,  A61P3/10 ,  A61P25/00 ,  A61P25/02 ,  A61P25/04 ,  A61P25/28 ,  A61P43/00 ,  C07K14/47 ,  C07K14/48 ,  C12N5/08

    CPC classification number: A61K38/185

    Abstract: PROBLEM TO BE SOLVED: To provide a means for preventing death of neurons that is one main cause of various nervous disorders from acute injury to long-term degeneration, and for elongating the life of neurons. SOLUTION: The invention discloses a method of protecting neurons in mammals from injury-induced pathological changes and a method of treating neuronal damage in mammals, by administering artemin or its agonist, which is unexpectedly and completely free of harmful side-effects (particularly hyperalgesia) associated with administration of neurotropic factors (for example NGF) in many cases. COPYRIGHT: (C)2010,JPO&INPIT

    Abstract translation: 要解决的问题：提供防止神经元死亡的手段，神经元是由急性损伤到长期变性的各种神经障碍的主要原因，并延长神经元的寿命。 解决方案：本发明公开了一种保护哺乳动物神经元免受损伤诱导的病理改变的方法，以及一种治疗哺乳动物神经元损伤的方法，通过施用意外和完全无有害副作用的artemin或其激动剂（ 特别是痛觉过敏）与许多情况下神经营养因子（例如NGF）的给药相关。 版权所有（C）2010，JPO＆INPIT

    Reduced-viscosity concentrated protein formulation
    8.
    发明专利
    Reduced-viscosity concentrated protein formulation 审中-公开
    降低粘度浓缩蛋白质配方

    公开(公告)号：JP2009167190A

    公开(公告)日：2009-07-30

    申请号：JP2009044568

    申请日：2009-02-26

    Applicant: Genentech Inc ,  Novartis Ag ,  ジェネンテック・インコーポレーテッドGenentech,Inc. ,  ノバルティス アクチエンゲゼルシャフト

    Inventor： LIU JUN ,  SHIRE STEVEN J

    IPC: A61K9/08 ,  A61K38/00 ,  A61K38/16 ,  A61K39/395 ,  A61K47/02 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26

    CPC classification number: A61K39/39591 ,  A61K9/0019 ,  A61K47/02 ,  A61K47/12 ,  A61K47/183 ,  Y10S435/80

    Abstract: PROBLEM TO BE SOLVED: To provide a method for reducing the viscosity of formulations containing proteins because concentrated protein formulations are increased in viscosity and the protein formulations are added with much lyoprotectant such as sugar and treated by freeze drying to keep its stability and thereby sugar increases intermolecular interaction to increase viscosity so the high viscosity formulations are hard in performing preparation, sucking into a syringe and hypodermic injection. SOLUTION: The protein formulations with high viscosity are reduced in viscosity without much injured in stability and biological activity by (1) increasing total ionic strength by adding a salt or a buffer component, or (2) decreasing (from about 4.0 to about 5.3) or increasing (from about 6.5 to about 12.0) pH of the formulations. COPYRIGHT: (C)2009,JPO&INPIT

    Abstract translation: 要解决的问题：提供一种减少含有蛋白质的制剂的粘度的方法，因为浓缩的蛋白质制剂的粘度增加，并且蛋白质制剂中加入了许多保护剂如糖，并通过冷冻干燥来保持其稳定性， 因此糖增加分子间相互作用以增加粘度，因此高粘度制剂在制备中很难进行，吸入注射器和皮下注射。 解决方案：通过（1）通过加入盐或缓冲剂组分提高总离子强度，或（2）降低（从约4.0至约4.0），具有高粘度的蛋白质制剂的粘度降低，稳定性和生物活性受到很大的损伤 约5.3）或增加（约6.5至约12.0）制剂的pH。 版权所有（C）2009，JPO＆INPIT

Patent Agency Ranking